NAPA, California, July 1 /PRNewswire/ --
Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that effective with the termination of its marketing agreement with Triax Aesthetics LLC for Pyratine-6(TM), all promotion, sales and distribution of Pyratine-6(TM) would be controlled and managed directly by the Company.
Phil Rose, Senetek's Chief Operating Officer stated, "We are building an infrastructure that has the expertise to establish Pyratine-6(TM) as the leading anti-aging product in the physician channel. The clinical data supporting Pyratine-6(TM) provides a clear and differential advantage over the competition. We are moving forward quickly and strategically without any looking back. We have the foundation and experience for success."
Bill O'Kelly, Senetek's Chief Financial Officer stated, "We are finalizing the operating and financial plan associated with the Company's promotion, sales and distribution of Pyratine-6(TM) and we will communicate appropriate aspects of the plan to our shareholders when the process is completed."
About Senetek PLC
Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.
This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
Web site: http://www.senetekplc.com
William O'Kelly, Chief Financial Officer of Senetek, PLC, +1-707-226-3900, ext. 102